Allogeneic Transplantation for CML in the TKI Era: Striking the Right Balance|
The majority of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) achieve excellent responses with sustained treatment; however, for an almost equal number of patients, an adequate response cannot be achieved with any of the currently available TKIs. For those patients who fail to respond adequately to TKIs, hematopoietic stem-cell transplantation offers the best prospect of long-term survival. [Nat Rev Clin Oncol] Abstract
Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.